Associate Professor of Medicine, Beth Israel Deaconess Medical Center
Hematology
Dr. Glenn J. Bubley, MD
|
|
Give Review
Glenn Bubley works in the field of Hematology. He received 4 awards: "America's Top Doctors", "America's Top Doctors for Cancer", "Boston Magazine" and "Meaningful Use Stage 1 Certification". Glenn Bubley is a published physician. He published 99 publications, including: 'Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.' Dr. Glenn J. Bubley accepts Medicare payments and is registered with Medicare.gov.
Publications
- Abiraterone treatment in castration-resistant prostate Cancer selects for progesterone responsive mutant androgen receptors.
- Whole transcriptome sequencing reveals extensive unspliced mRNA in metastatic castration-resistant prostate Cancer.
- A National Multicenter Phase 2 Study of Prostate-specific Antigen (PSA) Pox Virus Vaccine with Sequential Androgen Ablation Therapy in Patients with PSA Progression: E...
- A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate Cancer.
- Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate Cancer.
- Accuracy of EndoRectal Magnetic Resonance/TransRectal Ultrasound Fusion for Detection of Prostate Cancer During Brachytherapy.
- Clonal progression of prostate Cancers from Gleason grade 3 to grade 4.
- Models for prostate Cancer chemoprevention.
- Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate Cancer.
- Fatty acid synthase expression defines distinct molecular signatures in prostate Cancer.
- Association between prostate Cancer and serum testosterone levels.
- Prostate Cancer in a transgender woman 41 years after initiation of feminization.
- A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate Cancer.
- Prostasol and venous thromboembolism.
- Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate Cancer.
- MUC1 oncoprotein is a druggable target in human prostate Cancer cells.
- Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate Cancer.
- Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate Cancer during active surv...
- Dutasteride for the treatment of Prostate-related conditions.
- Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate Cancer displaying bone flare discordant with serologic response.
- Expanded prostate Cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the rout...
- Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate Cancer and is upregulated by treatment with CYP17A1 inhibitors.
- Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer.
- Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate Cancer.
- Hypoxia-inducible factor-1alpha (HIF-1alpha) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate Cancer.
- The challenge of herbal therapies for prostate Cancer.
- Detection of TMPRSS2-ERG fusion gene expression in prostate Cancer specimens by a novel assay using branched DNA.
- Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate Cancer.
- Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate Cancer.
- A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate Cancer who are refractory to docetaxel.
- Design and end points of clinical trials for patients with progressive prostate Cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clin...
- Hypoxia-inducible factor-2alpha: effect on radiation sensitivity and differential regulation by an mTOR inhibitor.
- A phase II study of mifepristone (RU-486) in castration-resistant prostate Cancer, with a correlative assessment of androgen-related hormones.
- Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate Cancer.
- Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate Cancer.
- Serum levels of insulin-like growth factor-1 and insulin-like growth factor-1 binding proteins after radical Prostatectomy.
- Biology of Prostate-specific antigen.
- Minimal effect of a low-fat/high soy diet for asymptomatic, hormonally naive prostate Cancer patients.
- Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate Cancer.
- Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate Cancer.
- Image contrast agents activated by Prostate specific antigen (PSA).
- Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate Cancer.
- Androgen receptor down-regulation in prostate Cancer with phosphorodiamidate morpholino antisense oligomers.
- Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition.
- Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate Cancer that prevents normoxia-induced degradation.
- Imatinib-induced regression of AIDS-related Kaposi's sarcoma.
- An image contrast agent selectively activated by Prostate specific antigen.
- An approach to heterobifunctional poly(ethyleneglycol) bioconjugates.
- Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate Cancer.
- Celecoxib versus placebo for men with prostate Cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy.
- The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.
- Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate Cancer cells.
- Microwave expedited synthesis of 5-aminocamptothecin Analogs: Inhibitors of hypoxia inducible factor HIF-1alpha.
- Androgen receptor phosphorylation and stabilization in prostate Cancer by cyclin-dependent kinase 1.
- Identification of cis-diamminedichloroplatinum(II) adducts in DNA from drug-treated human Cell nuclei.
- Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary Carcinoma.
- Combination of etanidazole with cyclophosphamide and platinum complexes.
- Spectrum of cis-diamminedichloroplatinum(II)-induced mutations in a shuttle vector propagated in human Cells.
- Viral infections and Cancer.
- Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's Lymphoma: a dose-finding study.
- Management of hypereosinophilic syndrome with chronic plasma- and leukapheresis.
- Effect of acyclovir on radiation- and chemotherapy-induced mouth lesions.
- Regional loss of chromosome 6 in two urological malignancies.
- The effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine on DNA repair and mutagenesis of herpes simplex virus type 1.
- Ribavirin enters cerebrospinal fluid.
- Inhibition of HSV-transformed murine cells by nucleoside Analogs, 2'-NDG and 2'-nor-cGMP: mechanisms of inhibition and reversal by exogenous nucleosides.
- Incorporation of 1-beta-D-arabinofuranosylcytosine into DNA and mutagenesis of herpes simplex virus type 1.
- Effects of Bloom's syndrome fibroblasts on genetic recombination and mutagenesis of herpes simplex virus type 1.
- Ribavirin treatment of the acquired immunodeficiency syndrome (AIDS) and the acquired-immunodeficiency-syndrome-related complex (ARC). A phase 1 study shows transient ...
- Effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine on the proliferation of herpes simplex virus type 1-transformed and thymidine kinase-deficient mouse Cells.
- Repair of DNA following incorporation of 1-beta-D-arabinofuranosylcytosine into herpes simplex virus type 1.
- Pericardial tamponade associated with myeloid metaplasia.
- Detection of circulating tumor cells in men with localized prostate Cancer.
- Mutation of the androgen-receptor gene in metastatic androgen-independent prostate Cancer.
- Detection of sequence-specific antitumor alkylating agent DNA damage from Cells treated in culture and from a patient.
- Differences in in vivo and in vitro sequence-specific sites of cisplatin-DNA adduct formation and detection of a dose-response relationship.
- Effect of DNA conformation on cisplatin adduct formation.
- Chromium(VI) treatment of normal human lung Cells results in guanine-specific DNA polymerase arrest, DNA-DNA cross-links and S-phase blockade of Cell cycle.
- Treatment of metastatic prostate Cancer. Lessons from the androgen receptor.
- Squamous Cell carcinoma of the renal pelvis with inferior vena caval extension.
- High dose bicalutamide for androgen independent prostate Cancer: effect of prior hormonal therapy.
- Frequent abnormalities of TSG101 transcripts in human prostate Cancer.
- Functional characterization of mutant androgen receptors from androgen-independent prostate Cancer.
- Loss of DNA mismatch repair facilitates reactivation of a reporter plasmid damaged by cisplatin.
- Selection for androgen receptor mutations in prostate Cancers treated with androgen antagonist.
- Tyrosine kinases expressed in vivo by human prostate Cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor.
- Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate Cancer: recommendations from the Prostate-Specific Antigen Working Gr...
- Hormonal predictors of prostate cancer: a meta-Analysis.
- A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate Cancer.
- Towards enzyme activated antiprostatic agents.
- Her-2-neu expression and progression toward androgen independence in human prostate Cancer.
- A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate Cancer.
- Target-directed enediynes: designed estramycins.
- Bone loss in men with prostate Cancer treated with gonadotropin-releasing hormone agonists.
- Is the flare phenomenon clinically significant?
- Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in Prostate epithelium.
- Loss of IFN-gamma production by invariant NK T cells in advanced Cancer.
- Prostate Cancer in the older man.
Schools
Michigan State University College Of Human Medicine
Conditions Treated
- Anal and Rectal Cancer
- Anemia
- Basal Cell Carcinoma
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- Boston Magazine
- Meaningful Use Stage 1 Certification
Education
-
Beth Israel Deaconess Medical Center -
Michigan State University College of Human Medicine
Hospital
-
Beth Israel Deaconess Medical Center
Drug Facts
| NPI NUMBER | 1881614485 | |
| NPPES Provider LastName | BUBLEY | |
| NPPES Provider FirstName | GLENN | |
| NPPES Provider ZIPCode | 022155400 | |
| NPPES Provider State | MA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 562.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 13.0 | |
| Percent Opioid Claims | 2.31 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1881614485 |
| Last Name Of The Provider | BUBLEY |
| First Name Of The Provider | GLENN |
| View All |
Similar Doctors
|
|
Dr. Marc D. Michaelson, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Edgar C. Henshaw |
|
|
Dr. Mary L. Peters, MD |
|
|
Dr. Bradley W. Blaser, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Allison Ackerman, MD |
|
|
Dr. Juan Godinez, MD |
|
|
Dr. Peter C. Yang, MD |
|
|
Dr. Arnold S. Freedman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Chakra P. Chaulagain, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sun Y. Oh, MD |
|
|
Dr. David J. Einstein, MD |
|
|
Dr. Boris Nicolai Bloch, MD
This Doctor is OpenDoctor Recommended.
|